Rebirth of science and technology academic master

Qin Yuanqing's work is still mainly based on scientific research. Xu Jiayi is his assistant in school affairs. He mainly focuses on the general direction. The usual internal coordination of the twenty-two school alliance is also left to Xu Jiayi.

As the laboratories of other schools continued to be completed, the instruments and equipment donated by Qin Yuanqing to the Twenty-Two School Alliance were gradually shipped out of the warehouse and shipped to those schools. Researchers and professors from various schools who originally went to Shuimu University for training also gradually They continued to leave Shuimu and returned to their respective schools, gearing up for a big fight.

Although Qin Yuanqing has repeatedly said in public that he does not want to be the leader of a college alliance, nor does Shuimu want to be the leader of the Twenty-Two Schools Alliance.

However, Qin Yuanqing is the largest financial backer of the twenty-two schools, and Shuimu University is now the number one university in Shuimu. According to the latest rankings in the world, it has entered the top ten universities, ranking exactly tenth in the world. Shuimu University will continue to release joint scientific research projects, and is actually a sponsor of the Twenty-Two Schools Alliance.

In this era where having breasts is a mother, Qin Yuanqing and Shuimu have become the de facto leaders of the Twenty-Two Schools Alliance and have a great influence on the other Twenty-one Schools.

Qin Yuanqing went to the laboratory again. Although Qin Yuanqing became the head of Shuimu, the Automotive Research Institute, the Aero Engine Research Institute, and the laboratory still maintained their original operating modes, and nothing changed. It's just that now the director of the life laboratory is Yan Ning, and the chemistry laboratory is Wu Shihao. With two Nobel Prize winners in charge, the laboratory development is going very smoothly.

Although there are no more earth-shattering achievements, various achievements are constantly being produced, the number of patents applied for is also constantly rising, and the value of the laboratory is constantly rising.

"Principal, regarding the current mechanism of myocarditis, from the feedback from sixteen hospitals, there is no deviation from the mechanism. The specific drug has entered the end of the first phase of clinical trials. So far, the results from various volunteers are relatively good. .Tolerance tests and pharmacokinetic tests have entered the final batch of trials. It is planned to start phase II clinical trials next year. We are currently communicating with superior departments to see if we can speed up the progress of clinical trials, so as to strive to bring specific drugs to the market as soon as possible. ." Yan Ning reported on the research on myocarditis. Relying on the myocarditis mechanism model and myocarditis unique factors developed by Qin Yuanqing, the laboratory became a leader in the field of heart disease in the world.

Qin Yuanqing nodded slightly.

The purpose of phase I clinical trials is mainly to study the human body's response and tolerance to new drugs, explore safe and effective dosages, propose reasonable dosing regimens and precautions, provide a basis for the dosing regimen of phase II clinical trials, and evaluate the drug. Study pharmacokinetics such as absorption, distribution, metabolism, and excretion in the body.

It can be said that phase I clinical trials are very important.

However, whether overseas or domestic, phase I clinical trials are often ignored and the focus is on phase II clinical trials.

Of course, this kind of thing cannot be brought to the table. It is a behind-the-scenes operation. It is rare for a laboratory to jointly conduct research with multiple hospitals and conduct sample tests on a large number of volunteers for a sufficient duration.

If we want to shorten the time of clinical trials and advance the progress of clinical trials openly, there is still a way to go in China, and that is to obtain the consent of superiors. It only takes a meeting or an announcement to solve the problem.

It's just that domestic officials who can reach high positions are undoubtedly smart people. How can they not know the risks involved? To put it bluntly, no superior leader is willing to take such risks and hand over his handle obediently. In the hands of the enemy, the enemy can use it to remove him from power at any time.

However, the laboratory is not comparable to other institutions. This achievement directly gave birth to three Nobel Prizes in Physiology or Medicine, and there were no flaws in the first-phase clinical trial for so long. The possibility of entering the second-phase clinical trial is still very big.

"Principal, during this period, pharmaceutical companies have been coming to us, seeking cooperation, including overseas pharmaceutical giants and domestic pharmaceutical giants. What do you mean?" Yan Ning hesitated for a moment, but still asked.

Since becoming the director of the life laboratory, Yan Ning has discovered that in addition to internal matters that need to be dealt with, external matters have come one after another. For example, those pharmaceutical giants also have great powers and have connected with her in various ways, making her unable to guard against them. , but some she can refuse, and some she cannot.

Although she is the director of the life laboratory, she is not qualified to decide such a matter. After all, Qin Yuanqing holds 90% of the laboratory's shares and is the real owner of the laboratory. She is just a researcher and a manager.

Qin Yuanqing looked thoughtful.

So far, 198 of China's top 500 companies have a market value of over 100 billion, of which 4 pharmaceutical companies have entered the top 500 companies in China, and 6 have a market value of over 100 billion. Hengrui Pharmaceutical ranks first in the market value of listed pharmaceutical companies with 246.5 billion yuan, followed by Kangmei Pharmaceutical with 111.8 billion yuan, Fosun Pharma with 108.2 billion yuan, CSPC Pharmaceutical Group with 104.6 billion yuan, and Huaxia Biologics with 104.3 billion yuan. Pharmaceuticals and Yunnan Baiyao worth 103.1 billion yuan each just exceeded 100 billion yuan.

From China's top 500 companies, we can also see that in the form of China's industrial structure, high-end manufacturing and Internet companies are undoubtedly at the forefront, with the highest market value.

But there is no doubt that the potential of medicine is also very large. After all, as people's income increases, the requirements for medical standards are also increasing day by day. The demand for medicine will naturally increase greatly, which means that the market is constantly expanding.

"I will handle this matter!" Qin Yuanqing pondered for a moment and said.

After understanding the situation in the laboratory, Qin Yuanqing left. After returning to the office, Qin Yuanqing asked Principal Huang, the vice president in charge of school enterprises, to come to his office.

Shuimu is also a school-enterprise group and is the most important school-enterprise group in Huaxia. The 'Shuimu Department' is very representative in terms of asset and liability structure, corporate governance structure, business operation model, etc. Its reform direction and effectiveness will directly determine the direction and effectiveness of Huaxia School. the final result of enterprise reform.

As early as 2015, the document on deepening the reform of the science and technology system and mechanism proposed by superiors proposed the gradual separation of high-tech enterprises from their affiliated enterprises. In May 2018, a document "Guiding Opinions on the Reform of the Enterprise System Affiliated to Higher Education Institutions" was issued, requiring the promotion of The enterprises affiliated to universities have been cleaned up and standardized, and the system has been improved to increase efficiency, prompting universities to focus on their main business of teaching and scientific research.

The scale and social impact of Shuimu's school-run enterprises are among the first in the country. In this school-enterprise reform, Shuimu University is both a pioneer and the one that encounters the greatest difficulties. There is no way, as the number one university in China, Shuimu must take the lead in implementing policy documents.

But at the same time, it is not easy to reform these high-quality assets. After all, there are a large number of excellent teams that have led the development of the school and enterprise for many years. Naturally, they are not very willing, which has stimulated fierce competition among all parties. .

"Principal Huang, how is the current school-enterprise reform going?" Qin Yuanqing asked.

"Oh, Principal, this matter is really tricky. I'm so busy that I'm exhausted. The difficulties are huge." Vice Principal Huang sighed and complained.

In 2003, Shuimu University integrated its industries and established a wholly-owned subsidiary, Shuimu Holdings. Shuimu University uses Shuimu Holdings as its platform to manage large-scale assets, covering industry groups such as technology industry, innovative services, technology finance, creative industries, and online education. It controls Tongfang Shares, Chengzhi Shares, Ziguang Shares, Ziguang Guowei, Eight A-share companies, including Ziguang University, TusGuhan, TusEnvironment, and Chenan Technology, have a combined market value of more than 500 billion yuan. According to this year's ranking, Shuimu Holdings ranks 87th among the top 500 domestic enterprises this year.

It can be said that there are three major departments under Shuimu Holdings, namely the Control Department, the Purple Light Department, and the Enlightenment Department.

Among them, the controlled capital refers to the listed companies directly controlled by Shuimu Holdings or its wholly-owned subsidiaries, including Tongfang Shares, Chengzhi Shares and Chenan Technology. Using the Unisoc Group as its platform, the Unisoc Group controls Unisoc, Unisoc Micro and Unisoc University, and holds shares in many listed companies such as Wenyi Technology; TusHoldings, through TusHoldings, controls TusGuhan and TusEnvironment. In addition, Ziguang Group and TusHoldings Group hold shares in a number of A-share companies, and Tongfang Group is the largest shareholder of Tellhow Technology.

Chengzhi Co., Ltd. is a high-tech listed company controlled by Shuimu University engaged in the production and sales of biological products and pharmaceuticals. Shuimu Holdings currently directly holds 11.76% of Chengzhi shares, and holds 33.44% through its wholly-owned subsidiary Chengzhi Kerong. Chen'an Technology, another listed company under the Department of Shuimu Holdings, mainly relies on the technical advantages of the Public Safety Research Institute of Shuimu University to engage in the industrialization of public safety and emergency technologies. Shuimu Holdings directly holds 8.16% of the shares of Chen'an Technology, through a wholly-owned Subsidiary Shuimu Kongchuang holds 18.68% of the shares.

As for Tongfang Co., Ltd., it occupies a special position in the Shuimu Control Group because its scale and popularity have greater advantages than the other two listed companies. Tongfang Holdings is the only A-share listed company directly controlled by Shuimu Holdings. The latter relies on the scientific research strength and talent platform of Shuimu University, takes the road of integrating industry, academia and research, and is positioned as a diversified and comprehensive technology industry incubator, committed to China's high-tech achievements. transformation and industrialization. As of now, Shuimu Holdings directly holds 25.75% of Tongfang’s shares, and Ziguang Group holds 2.35%.

Among the school-run enterprises of Shuimu University, the Ziguang Department is the largest and most complex. Tsinghua Unigroup is a leading digital infrastructure and service company and focuses on developing the electronic components and equipment manufacturing industry. As of the end of 2018, Ziguang Group had more than 40,000 employees worldwide and total assets of approximately 270 billion yuan. Ziguang Group is the third largest mobile phone chip design company in the world, accounting for more than 20% of the global SIM card chip market share. Shuimu Holdings holds 51% of the shares of Ziguang Group, and the other 49% belongs to Jiankun Investment. The largest shareholder of Jiankun Investment is Zhao Weiguo, who holds 70% of the shares. The other two shareholders are Li Yi and Li Luyuan, each holding 15% of the shares.

The platform of TusHoldings is TusHoldings. The latter’s holding subsidiary TusTech Services is the controlling shareholder of TusGuhan and TusEnvironment, with direct shareholding ratios of 29.44% and 16.56% respectively. TusTech Services also operates through two wholly-owned subsidiaries. The company holds 7.48% shares of Tus-Environment. TusHoldings is a science and technology investment holding group established by Shuimu University focusing on the field of science and technology services. It is the development, construction and operation management unit of Shuimu Science and Technology Park. TusHoldings’ official website states that the company’s total assets under management exceed 200 billion yuan.

In addition to Shuimu Holdings, there is also the 'College Student Entrepreneurship Foundation' established by Shuimu University in the past ten years. The purpose of this foundation is to help Shuimu college students start their own businesses by providing entrepreneurial funds to obtain this share. This part should not be underestimated. So far, those who have participated in the shares The company, calculated based on the market value of its shares, has also expanded sharply to 180 billion yuan, and because the companies it participates in are all in the stage of rapid expansion, the value of this part is still growing.

Qin Yuanqing also has some headaches. To be honest, many people are very resistant to school-enterprise reform, because Shuimu's school-run enterprises are all high-quality enterprises. With Shuimu's backing, these enterprises can get technical support from Shuimu. In addition, Shuimu has sufficient funds in recent years and does not need to suck blood from these companies, which has led to the continuous development and growth of these companies.

However, a document from superiors forced Shuimu University to implement it. However, not long after, Shuimu University's restructuring encountered great difficulties and it was difficult to continue to implement it.

"Alas, I was originally thinking of supporting Chengzhi Shares and licensing some patents from the Life Laboratory to Chengzhi Shares. It seems that my thinking was too simple!" Qin Yuanqing said with a sigh.

Principal Huang was horrified and said with a wry smile: "Principal, don't do this. Now we are one of the top two. It is really troublesome to deal with school-run enterprises. If you continue to support Chengzhi Shares, although you can Rapidly growing Chengzhi Shares will put us in greater trouble. Isn’t this a blatant rebellion against our superiors?”

Qin Yuanqing rubbed his temples. To be honest, Qin Yuanqing didn't think highly of domestic pharmaceutical companies, whether they were state-owned or private companies. It is true that the investment in scientific research by these pharmaceutical giants was appalling, even if he would After licensing patents to them, Qin Yuanqing suspected that these pharmaceutical giants would not take advantage of the opportunity to strengthen themselves and improve their scientific research capabilities to enhance their strength. Instead, they would become fat and full of oil.

This goes against Qin Yuanqing's original intention. He hopes that China's pharmaceutical companies can focus on the whole world and improve their strength to compete with overseas pharmaceutical giants, instead of letting China become a place for overseas pharmaceutical giants to arbitrarily extract excess profits.

Since leaving it to a school-run company was not feasible, and he did not want to cooperate with state-owned or private pharmaceutical giants, Qin Yuanqing couldn't help but think about setting up a pharmaceutical company by himself, and then using the laboratory's patents to develop and grow step by step, becoming The new pharmaceutical giant.

Pfizer, for example, has become the world's pharmaceutical giant, not because the laboratory accidentally invented the little blue pill. Since then, it has been in an invincible position and conquered the world with the help of the little blue pill.